{
    "nct_id": "NCT03662126",
    "official_title": "A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment",
    "inclusion_criteria": "* Confirmed diagnosis of PMF, post-PV MF or post-ET MF (WHO)\n* High, intermediate-2, or intermediate-1 risk Dynamic International Prognostic System (DIPSS)\n* Failure of prior treatment with JAK inhibitor\n* ECOG â‰¤ 2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior splenectomy\n* Splenic irradiation within 3 months prior to randomization\n* History of major hemorrhage or intracranial hemorrhage within 6 months prior to randomization\n* History of stroke, reversible ischemic neurological defect or transient ischemic attack within 6 months prior to randomization\n* Prior MDM2 inhibitor therapy or p53-directed therapy\n* Prior allogeneic stem-cell transplant or plans for allogeneic stem cell transplant\n* History of major organ transplant\n* Grade 2 or higher QTc prolongation (> 480 milliseconds per NCI-CTCAE criteria, version 5.0)",
    "miscellaneous_criteria": ""
}